Psyence BioMed achieves clinical milestone with psilocybin study success.

Psyence Biomedical Ltd. announced a major clinical milestone in its Phase IIb trial for nature-derived psilocybin in palliative care patients. The trial aims to treat Adjustment Disorder using psychotherapy and a natural psilocybin formulation. The Company has successfully dosed multiple patients across multiple trial sites, advancing its position as a global leader in late-stage psychedelic drug development.